Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs); By Therapeutic Areas; By Indication; By Approach; By Region; Segment Forecast, 2023 - 2032
- Published Date:Dec-2023
- Pages: 116
- Format: PDF
- Report ID: PM1687
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global human microbiome therapeutics market was valued at USD 508.70 million in 2022 and is expected to grow at a CAGR of 22.7% during the forecast period.
The human microbiome therapeutics market has experienced rapid growth in recent years. Increasing research and understanding of the human microbiome's role in health and disease has fueled the development of new therapies. The market is also driven by the rising prevalence of conditions such as gastrointestinal disorders, autoimmune diseases, and metabolic disorders, which are believed to be influenced by the microbiome.
To Understand More About this Research: Request a Free Sample Report
Moreover, sequencing technologies and bioinformatics advancements have enhanced our ability to characterize and manipulate the microbiome, facilitating the development of more targeted and effective therapies. Additionally, regulatory bodies have provided guidelines and frameworks to support the development and approval of microbiome-based therapeutics, further promoting market growth.
Human microbiome therapeutics are products or interventions that aim to modulate the composition or activity of the microbiome to promote health or treat diseases. These therapeutics can be categorized into probiotics, prebiotics, fecal microbiota transplantation (FMT), and other microbiome-based therapies. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. Prebiotics, conversely, are substances that selectively stimulate the growth or activity of beneficial organisms in the gut. FMT involves the transfer of fecal matter from a healthy donor to a recipient to restore a balanced microbiome.
For Specific Research Requirements: Request for Customized Report
The outbreak of the COVID-19 pandemic has significantly impacted the market. It is increasing the focus on immune health, leading to the development of microbiome-based COVID-19 therapies, disrupting clinical trials, emphasizing hygiene practices that can affect the microbiome, and causing supply chain disruptions. Despite these challenges, the market continues to advance with a growing recognition of the microbiome's importance in infectious diseases. Ongoing research and the potential for microbiome-based interventions to support immune health and improve outcomes in COVID-19 patients indicate the continued relevance of microbiome therapeutics in managing public health crises.
We strive to offer our clients the finest in market research with the most reliable and accurate research findings. We use industry-standard methodologies to offer a comprehensive and authentic analysis of the Human Microbiome Therapeutics Market. Besides, we have stringent data-quality checks in place to enable data-driven decision-making for you.
Industry Dynamics
Growth Drivers
- Rising infectious diseases
The human microbiome therapeutics market is experiencing significant growth, primarily driven by the increasing incidence of illnesses related to dysbiosis in the gut microbiota. Additionally, a substantial allocation of funds for biological drug discovery and research is fueling this growth.
There is a growing demand for precise, dependable, and prompt therapies to address hepatic encephalopathy, phenylketonuria, C. difficile infection, and multidrug-resistant urinary system infections. This global demand is expected to contribute to the expansion of the market.
The granting of orphan drug designations and advanced treatment designations for human microbiome therapies is anticipated to accelerate the introduction of new pharmaceuticals in the microbiome therapeutics industry. This industry holds significant potential for expansion as there are currently over 120 medication candidates in various stages of discovery, which will contribute to the growth of the microbiome therapeutics market.
Report Segmentation
The market is primarily segmented based on product, therapeutic area, indication, approach, and region.
|
By Product |
By Therapeutic Area |
By Indication |
By Approach |
By Region |
|
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Therapeutic Area Analysis
- Infectious disease segment anticipated to hold fastest growth over the forecast period
The infectious disease segment is projected to experience the fastest growth during the forecast period. This can be attributed to the increasing awareness of the negative consequences of antibiotic usage on natural flora, which has emphasized the need for targeted treatments for infectious disorders. Additionally, the rising prevalence of illnesses caused by microbial dysbiosis due to antibiotic therapy and the growing number of clinical studies for developing microbiome-based therapeutics are driving the expansion of this segment.
Consequently, advancements in diagnostic instruments and a greater understanding of early diagnosis propel the market's growth. The frequency of infectious disorders in both developed and emerging regions will contribute to the success of the infectious disease diagnostics industry. Furthermore, the rising prescription rates for diagnostic tests related to contagious diseases and a growing focus on preventive care are expected to fuel the demand for infectious disease diagnostics throughout the forecast period.
By Product Analysis
- Probiotics segment expected to dominate the market during forecast period
The probiotics category is expected to dominate the human microbiome therapeutics industry during the projected period. Probiotics, such as bacteria and yeasts, offer various health benefits when consumed. These benefits range from supporting digestion and immune function to promoting overall well-being.
Currently, small molecule treatments hold the largest market share within the industry. Small molecule treatments refer to therapeutic substances composed of small organic molecules widely used in medical practice. The widespread usage of small molecule treatments has contributed to their significant market presence.
By Indication Analysis
- Diabetes segment is projected to grow at the fastest rate during projected period
The diabetes category is projected to experience the fastest growth rate during the forecast period. This can be attributed to good clinical data demonstrating the effectiveness of live biotherapeutics in diabetes treatment and the presence of a pipeline of upcoming therapies set to enter the market. The positive outcomes in clinical trials and the anticipated introduction of new therapies drive the expansion of the diabetes segment. Clostridium difficile disease emerged as the most prevalent illness, primarily attributed to increased cross-reactions with medications and lifestyle factors such as poor dietary habits.
Regional Insights
- North America dominated the global market in 2022
North America dominated the global industry in 2022 and is likely to maintain its dominance over the anticipated period. The North American market for human microbiome therapeutics is thriving and holds a prominent position within the healthcare industry. This region is at the forefront of research and development, with robust investments, clinical trials, and collaborations driving advancements.
The well-established healthcare infrastructure, strong regulatory framework, and the prevalence of chronic diseases provide a fertile ground for the growth of human microbiome therapeutics in North America. Key market players and biotechnology companies dedicated to microbiome research contribute to the market's expansion, further fueling innovation and commercialization efforts.
Market Key Players & Competitive Insight
The market is driven by a growing global demand for precise and dependable therapies to address specific conditions such as hepatic encephalopathy, phenylketonuria, C. difficile infection, and multidrug-resistant urinary system infections. Companies that can effectively leverage these growth drivers, stay at the forefront of microbiome research, secure strong intellectual property rights, and navigate the complex regulatory environment are poised for success in this expanding and competitive industry.
Some of the major players operating in the global market include:
- 16S Technologies
- 4D Pharma PLC
- 5QBD-Biotech
- BiomX
- Biotagenics
- Carbiotix
- ClearB Therapeutics
- Commense
- CoreBiome
- DermBiont
- E.I. du Pont de Nemours and Company
- Embion Technologies
- Enterome Bioscience
- Exeliom Biosciences
- Ferring Pharmaceuticals
- Finch Therapeutics
- GNUbiotics Sciences
- GoodBelly
- GoodGut
- Holobiome
- Hyggut
- Igen Biolab Group
- Lactobio
- Oxidien Pharmaceuticals, LLC
- Second Genome
- Seres Therapeutics
- Synlogic
- UBiome
- Vedanta Biosciences
- ViThera Pharmaceuticals
Recent Developments
- In April 2023, US regulators approved Vowst, a pill derived from human faeces, to treat C. difficile infection. Developed by Seres, it belongs to the emerging field of microbiome therapeutics, aiming to restore gut bacteria balance to prevent disease. Nestlé and Flagship Pioneering back the therapy.
- In September 2022, Stanford University researchers have created a synthetic microbiome with over 100 bacterial species, offering a breakthrough in studying the gut microbiome's impact on health. The ability to manipulate individual species will enhance understanding and pave the way for novel microbiome therapies.
Human Microbiome Therapeutics Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 623.20 million |
|
Revenue forecast in 2032 |
USD 3,917.01 million |
|
CAGR |
22.7% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments Covered |
By Product, By Therapeutic Areas, By Indication, By Approach, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
Gain profound insights into the 2024 Human Microbiome Therapeutics Market with meticulously compiled statistics on market share, size, and revenue growth rate by Polaris Market Research Industry Reports. This thorough analysis not only provides a glimpse into historical trends but also unfolds a roadmap with a market forecast extending to 2029. Immerse yourself in the comprehensive nature of this industry analysis through a complimentary PDF download of the sample report.
Browse Our Top Selling Reports
Vernaldehyde Market Size, Share 2024 Research Report
Reach Stacker Market Size, Share 2024 Research Report
Ozone Generator Market Size, Share 2024 Research Report
© 2024 Polaris Market Research and Consulting. All rights reserved
